Biotechnology News 8 October 2025

Sana Biotech Shares Skyrocket on 100x Hype – What’s Behind the Rally?

Stock Surge Fueled by ‘100-Bagger’ Tweet On Oct. 15, SANA spiked as investors reacted to hedge fund manager Eric Jackson’s bullish call. In a post on X (formerly Twitter), Jackson proclaimed: “Biotech

15 October 2025

Recursion RXRX Stock Skyrockets: AI Breakthroughs and Big Pharma Deals Ignite Biotech Surge

Volatile Stock Performance in October 2025 Recursion’s stock showed wild swings in early October. On Oct 7, 2025 the shares fell about 5.4% to ~$5.23 amid a broad market slump nasdaq.com. The

15 October 2025

Artificial Intelligence · Biotechnology · Investment Trends · NASDAQ:RXRX · Pharma Industry · Stock Market

Origin Agritech’s SEED Stock Skyrockets 92% on China Seed Breakthroughs & Trade Buzz

SEED Stock Soars on Market Momentum Origin Agritech’s stock skyrocketed this week, delivering eye-popping gains for investors. On Tuesday night, SEED shares surged over 92% in after-hours trading following a flurry of

15 October 2025

Agriculture · Biotechnology · China Market · NASDAQ:SEED · Stocks · Trade News

Evaxion (NASDAQ:EVAX) Stock Rockets After AI-Powered Cancer Vaccine Breakthrough

Evaxion’s stock jump in mid-October comes as the company lines up important clinical updates and validates its AI-driven vaccine technology. On Oct 13, Evaxion announced it will present two-year data from its

15 October 2025

Artificial Intelligence · Biotechnology · Cancer Research · Medical Innovation · NASDAQ:EVAX · Stock Market

Arcadia Biosciences Stock Rockets Amid Trade News – What’s Behind RKDA’s Wild Ride?

In-Depth: Arcadia’s stock price (RKDA) has been extremely volatile in October 2025, jumping ~68% pre-market on Oct 15. The rally was sparked by a Trump tweet on China trade and follows mixed

15 October 2025

Biotechnology · Company News · Financial Analysis · Investing · NASDAQ:RKDA · Stock Market

Genprex (NASDAQ:GNPX) Stock Skyrockets 40% on Lung Cancer Gene Therapy Breakthrough

Stock Price & Recent Performance Genprex shares have been extremely volatile. After surging over 30% during regular hours on Oct 14, 2025, to about $0.25, the stock jumped another 41% in after-hours

15 October 2025

Biotechnology · Gene Therapy · Health News · Lung Cancer · NASDAQ:GNPX · Stock Market

Intellia Therapeutics Stock Soars on Gene-Editing Breakthrough – Analysts Eye 70–100% Upside

Intellia Background and Pipeline Intellia was an early pioneer of in-vivo CRISPR therapy. Based in Cambridge, MA, it was among the first to administer CRISPR-Cas9 therapies directly into patients ts2.tech. In 2021

9 October 2025

Biotechnology · Gene Editing · Investment Analysis · NASDAQ:NTLA · Pharma News · Stock Market

AI Drug Discovery Goldmine? Inside Recursion Pharma’s Wild Stock Surge and What’s Next

Latest News (Oct 7–Oct 9, 2025) Stock Performance & Technical Analysis After languishing through the summer, Recursion’s share price came to life in early October 2025. By Oct 8 the stock had

9 October 2025

Artificial Intelligence · Biotechnology · Drug Discovery · NASDAQ:RXRX · Pharma Industry · Stock Market

Xenetic Biosciences (XBIO) Stock Skyrockets – Is the Biotech’s 2025 Rally for Real?

Stock Performance: The 2025 Rollercoaster Ride Xenetic’s stock was relatively quiet for most of 2025 until early October, when it suddenly erupted. By Oct 8, 2025, XBIO had skyrocketed to levels not seen

8 October 2025

2025 Outlook · Biotechnology · Financial News · NASDAQ:XBIO · Pharma Investing · Stock Market

Moderna, Inc. (MRNA) Stock Update – Oct 8 2025: Will the mRNA Trailblazer Bounce Back or Sink Further?

Detailed Report 1. Stock Performance and Valuation Moderna’s stock was a market darling during the pandemic but has suffered a long decline. On Oct 7 2025 (the last trading day before the U.S. Columbus

8 October 2025

Biotechnology · Company News · Financial Analysis · Investing · NASDAQ:BNTX · NASDAQ:MRNA · NYSE:MRK · Stock Market

Intellia Therapeutics (NTLA) Soars on CRISPR Breakthroughs – Latest Updates & Stock Outlook

Why Intellia Therapeutics’ Stock Could Be a Gene‑Editing Goldmine in 2025 – Deep Dive into NTLA’s Prospects

Quick Facts (as of 8 Oct 2025) Recent Performance and News Phase 1 data fuels rally Intellia’s October rally was triggered by longer‑term Phase 1 results for nexiguran ziclumeran (nex‑z), an in‑vivo CRISPR therapy for transthyretin

8 October 2025

Biotechnology · Company Analysis · Gene Editing · Investment Opportunities · NASDAQ:NTLA · Stocks

CRISPR Therapeutics Stock Update (Oct 8 2025): Why Gene‑Editing Bulls See Big Upside

Stock Price, Volume and Sentiment According to AAII, CRSP’s share price on 8 Oct 2025 closed at $77.727, up 10.06 % from the previous close. The stock traded between $70.77 and $78.38 that day and

8 October 2025

Biotechnology · Gene Editing · Investment Analysis · Market Trends · NASDAQ:CRSP · Stocks

Biotechnology News 8 October 2025 - 15 October 2025